Rexahn Pharmaceuticals - RNN | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Rexahn Pharmaceuticals - RNN

An SI Board Since April 2010

Posts	SubjectMarks	Bans	Symbol
5	1	0	RNN

Emcee: caly	Type: Moderated

Introduction Market Data Compact

Website: rexahn.com

SEC Filings: sec.gov

Press Releases: rexahn.com

Portfolio: rexahn.com

Lead drug candidates in Phase II trials:

Serdaxin® a best-in-class therapy for treating depression, and potentially Parkinson’s Disease and Alzheimer’s Disease. (April, 2010 Phase II protocol submitted to FDA for PD.)

Zoraxel™ a first-in-class CNS-based therapy for treating sexual dysfunction. (March 2010 Phase IIb protocol submitted to FDA)

Archexin® a first-in-class AKT-inhibitor therapy for treating various cancers, such as pancreatic cancer, renal cell carcinoma (RCC), glioblastoma, and cancers of the ovary and stomach. (Phase II initiated in March 2009, results on humans expected in 2010.)

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
5	Rexahn: Holes Galore in Serdaxin Data thestreet.com Interesting comments follo	caly	2	4/19/2010
4	So in their first PR they try to ignore that they whiffed on the primary endpoin	tuck	-	4/14/2010
3	Rexahn Pharmaceuticals Issues Additional Comments and Clarifications on its Phas	caly	-	4/14/2010
2	Rexahn Pharmaceuticals Announces Phase IIa Study Results of Serdaxin in Major De	caly	-	4/13/2010
1	RNN Coverage in CP Reports: cpreports.com	caly	-	4/12/2010

Go to reply# or date (mm/dd/yy):